Are Barclays PLC, GlaxoSmithKline plc & Tesco PLC Classic Contrarian Buys?

You’d have to be very contrarian to buy Barclays PLC (LON: BARC), GlaxoSmithKline plc (LON: GSK) and Tesco PLC (LON: TSCO) right now, says Harvey Jones

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Barclays (LSE: BARC), GlaxoSmithKline (LSE: GSK) and Tesco (LSE: TSCO) are some of the most renowned companies on the FTSE 100, and the most troubled.

Over the last year, Barclays is down 19%, Glaxo is down 12% and Tesco is down a whopping 39%. These stocks are falling knives, no doubt about it. But are they classic contrarian buys?

On The Contrary…

Investopedia defines contrarian as “an investment style that goes against prevailing market trends by buying assets that are performing poorly and then selling when they perform well”.

So yes, all three are classic contrarian buys, given the negative prevailing market view. The question is whether they can fulfil the second part of the bargain, by performing well and giving you the opportunity to sell at a profit. 

BarclaysBarclays is cheap, but not that cheap. Today’s valuation of 13.7 times earnings is almost exactly in line with the FTSE 100 average of 13.68 times. Strong forecast earnings per share (EPS) growth of 26% this year and 27% next should improve matters, however, putting it on a tempting forward valuation of 8.6 times earnings for December 2015.

But this is also a troubled organisation with a besmirched reputation that is currently over going a major overhaul, shrinking its investment banks and cutting thousands of jobs worldwide.

It also faces competition at home from a heap of challenger banks, including M&S, Tesco, Virgin and TSB, and a regulatory assault that could throw the key current account market wide open.

Barclays will also suffer from what Neil Woodford calls “fine inflation”, as regulators ramp up their penalties. Nomura reckons Barclays could face fines totalling £7 billion in the next few years.

Any recovery will take years, but I reckon Barclays will endure. Contrarians are supposed to be brave, aren’t they? And very patient.

gskGlaxoSmithKline has been hit hard by the Chinese bribery scandal, but this isn’t an isolated case. It faces similar allegations in Iraq, Poland, Syria, Lebanon and Jordan.

It is also facing probes by the US Department of Justice and Securities and Exchange Commission, and the UK’s Serious Fraud Office. A multi-million-dollar settlement beckons.

Glaxo has other worries. Its US pharmaceuticals and vaccines turnover fell 10% in Q2, while group sales fell 4% and EPS tumbled 12%.

Credit Suisse has just slashed its earnings forecasts, noting that Glaxo’s shares trade at a 10% price-to-earnings premium to other major European pharmaceutical groups.

Recent successful early trials of an Ebola vaccine are a rare bright point. The real attraction is the yield, now a healthy 5.4%. And you can buy Glaxo at 12.8 times earnings, a rare discount in a stock that is normally fully valued.

Glaxo will eventually shrug off its scandals, and you get a juicy yield while you wait. I have rarely seen a more classic FTSE 100 contrarian buy (and hold).

TescoTesco looks more like a classical tragedy than a classic contrarian buy.

New boss Dave Lewis has pledged to battle against the fates and furies, but he has an epic fight on his hands. The UK’s biggest retailer has been brought low by a combination of hubris and hungry challengers, in the shape of barbarians Aldi and Lidl.

Like Barclays, Tesco is in a beleaguered sector, plagued by disenchanted customers. Turning around public perception will be a Herculean task. Cutting prices without destroying margins won’t be easy, either.

Following the recent dividend cut, loyal investors don’t even get the luxury of an attractive yield.

What you do get is a brutally cheap valuation of just 7.1 times earnings. If the wheel of fortune swings in favour of Lewis, now could be a fabulous time to buy.

But this contrarian stock is just too contrarian for me.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. The Motley Fool UK owns shares of Tesco. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »